Abstract
No public abstract is available from the verified source records.
Michael P. Randall, Mazie Tsang, Jazlynn Gee, Chitoh Yung, James L. Rubenstein
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Primary central nervous system lymphoma
10.1038/s41572-023-00439-0 · 2023
The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades
10.1093/neuonc/nox187 · 2018
Outcomes of the oldest patients with primary CNS lymphoma treated at Memorial Sloan-Kettering Cancer Center
10.1093/neuonc/nos207 · 2012
Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202)
10.1200/jco.2012.46.9957 · 2013
Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial
10.1038/s41375-022-01582-5 · 2022
Clinical outcomes of etoposide and cytarabine as consolidation in elderly patients with primary CNS lymphoma
10.1093/oncolo/oyae059 · 2024
Comparison of thiotepa-based conditioning regimens for older adults with primary diffuse large B-cell lymphoma of the central nervous system undergoing autologous hematopoietic cell transplantation
10.1016/j.jtct.2024.09.015 · 2024
Long-term survival in primary CNS lymphoma
10.1200/jco.1998.16.3.859 · 1998
Confidence 0%
Delayed neurotoxicity in primary central nervous system lymphoma
10.1001/archneur.62.10.1595 · 2005
Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial
10.1016/s2352-3026(15)00074-5 · 2015
Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07
10.1200/jco.2003.03.036 · 2003
Second-line treatment for primary central nervous system lymphoma
10.1038/sj.bjc.6690083 · 1999
Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma
10.1182/bloodadvances.2017014845 · 2018
10.1093/annonc/mdz032
10.1093/annonc/mdz032 · 2019
Low-dose lenalidomide maintenance after induction therapy in older patients with primary central nervous system lymphoma
10.1111/bjh.15787 · 2019
Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma
10.1200/jco.2005.13.524 · 2005
Methotrexate re-challenge for recurrent primary central nervous system lymphoma
10.1007/s11060-014-1370-0 · 2014
Treatment of relapsed central nervous system lymphoma with high-dose methotrexate
10.1158/1078-0432.ccr-04-0159 · 2004
Trial in progress - alliance A051901 - phase I trial of methotrexate, rituximab, lenalidomide, and nivolumab (Nivo-MR2) induction followed by lenalidomide and nivolumab maintenance in primary central nervous system lymphoma (PCNSL)
10.1182/blood-2024-209238 · 2024
Identification of genomic biomarkers of disease progression and survival in primary CNS lymphoma
10.1182/bloodadvances.2024014460 · 2025
High-dose chemotherapy and autologous stem cell transplant in elderly patients with primary CNS lymphoma: a pilot study
10.1182/bloodadvances.2020002064 · 2020
A pilot study of axicabtagene ciloleucel (axi-cel) for relapsed/refractory primary and secondary central nervous system lymphoma (PCNSL and SCNSL)
10.1200/jco.2024.42.16_suppl.2006 · 2024
No additional external references are available.